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Objectives The purpose of this study is to compare post-dilation strategies of nitinol self-expanding stents implanted in the
superficial femoral artery of diabetic patients with peripheral arterial disease.
Background Endovascular treatment of superficial femoral artery disease with nitinol self-expanding stents is associated with
high rates of in-stent restenosis in patients with diabetes mellitus.
Methods We conducted a prospective, multicenter, randomized, controlled clinical trial of diabetic patients to investigate
whether post-dilation of superficial femoral artery nitinol self-expanding stents using a cryoplasty balloon re-
duces restenosis compared to a conventional balloon. Inclusion criteria included diabetes mellitus, symptomatic
peripheral arterial disease, and superficial femoral artery lesions requiring implantation of stents 5 mm in di-
ameter and 60 mm in length. Primary endpoint was binary restenosis at 12 months, defined as 2.5-fold in-
crease in peak systolic velocity by duplex ultrasonography.
Results Seventy-four patients, with 90 stented superficial femoral artery lesions, were randomly assigned to post-dilation
using cryoplasty (n  45 lesions) or conventional balloons (n  45 lesions). Mean lesion length was 148  98 mm,
mean stented length was 190  116 mm, mean stent diameter was 6.1  0.4 mm, and 50% of the lesions were
total occlusions. Post-dilation balloon diameters were 5.23  0.51 mm versus 5.51  0.72 mm in the cryoplasty and
conventional balloon angioplasty groups, respectively (p  0.02). At 12 months, binary restenosis was significantly
lower in the cryoplasty group (29.3% vs. 55.8%, p  0.01; odds ratio: 0.36, 95% confidence interval: 0.15 to 0.89).
Conclusions Among diabetic patients undergoing implantation of nitinol self-expanding stents in the superficial femoral artery,
post-dilation with cryoplasty balloon reduced binary restenosis compared to conventional balloon angioplasty. (Study
Comparing Two Methods of Expanding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease [COBRA];
NCT00827853) (J Am Coll Cardiol 2012;60:1352–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.042Percutaneous revascularization of superficial femoral artery
(SFA) lesions can be accomplished with high procedural
success rates (1). Implantation of nitinol self-expanding
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October 9, 2012:1352–9 Cryoplasty Post-Dilation of Peripheral StentsRestenosis rates, however, remain high (30% to 50% at 1 year)
(2,3). Patients with diabetes mellitus are at an increased risk of
restenosis because of exaggerated intimal hyperplasia (4,5).
Cryoplasty is performed with a Food and Drug Adminis-
tration approved angioplasty balloon catheter (PolarCath, Bos-
ton Scientific, Natick, Massachusetts) that is positioned at the
arterial lesion and inflated with nitrous oxide, which cools the
surface of the balloon and freezes the plaque in the artery (6).
his action has 3 potential beneficial effects: 1) weakens
laque, thereby promoting uniform dilation resulting in less
essel trauma; 2) reduces vessel wall recoil; and 3) induces
mooth muscle cell apoptosis, limiting neointima formation
7).
We hypothesized that cryoplasty, by inducing smooth
uscle cell apoptosis when applied for post-dilation of SFA
tents, will reduce restenosis compared to a conventional
alloon post-dilation strategy. To test our hypothesis, we
onducted a pilot, randomized trial comparing cryoplasty to
onventional balloon post-dilation of nitinol self-expanding
tents implanted in the SFA of diabetic patients presenting
ith symptomatic peripheral arterial disease.
ethods
tudy design. The COBRA (Study Comparing Two
ethods of Expanding Stents Placed in Legs of Diabetics
ith Peripheral Vascular Disease) study was approved by
he institutional review boards of all 4 participating centers,
nd all patients provided written informed consent.
From August 2008 to December 2010, consecutive pa-
ients referred for endovascular treatment of SFA disease
ere screened for enrollment at 4 participating centers.
atients who satisfied all the inclusion criteria and had none
f the exclusion criteria were randomly allocated in a 1:1
ashion to either cryoplasty or conventional balloon post-
ilation of the SFA stented segment.
Key clinical inclusion criteria were diabetes mellitus
insulin requiring or noninsulin requiring), referral for
ndovascular treatment of peripheral arterial disease for
evere intermittent claudication (Rutherford-Becker stage
), chronic critical limb ischemia with rest pain (Rutherford-
ecker stage 4), or chronic critical limb ischemia with ischemic
lcers (Rutherford-Becker stage 5) symptoms.
Key angiographic inclusion criteria were de novo SFA
esion with 50% diameter stenosis by visual estimation
equiring implantation of self-expanding stent 60 mm in
ength and 5 mm in diameter. Patients were excluded if
hey were allergic to aspirin, clopidogrel, or iodine-based
adiographic contrast, had obstructive (50% diameter
tenosis) iliofemoral artery disease, or absence of at least
-vessel infrapopliteal run-off. All patients had radio-
paque tape in the imaging field as a reference for deter-
ining vessel dimensions. A SFA lesion with 50% diam-
ter stenosis was considered significant. The selection of
re-dilation, stent deployment, and adjunctive pharmaco-ogic therapy was at the discretion of the primary operator. sndpoints. The primary study
ndpoint was binary restenosis,
s assessed by duplex ultrasonog-
aphy performed at 12 months
ost-procedure or earlier if clin-
cally indicated. Binary restenosis
as defined as 2.5-fold in-
rease in peak systolic velocity within the stented segment
nd within 10 mm of its proximal and distal edges to that
ecorded proximal to the stented segment or by the presence of
n occluded stent with no flow. Secondary endpoints included
hange of resting ankle-brachial index (ABI) and symp-
oms (Rutherford-Becker stages) at 12 months post-
rocedure. Patients were asked to complete a walking
mpairment questionnaire (score range 0 to 14,080) pre-
ntervention, and then every 6 months for the first year
ost-procedure (8).
All analyses were performed in a blinded fashion at the
eterans Affairs North Texas Clinical Angiographic and
ltrasound Core Laboratory, and clinical adjudication and
dverse events monitoring were performed by an indepen-
ent data oversight and safety monitoring board.
linical assessment. All patients underwent a complete
edical history and physical examination, including assess-
ent of symptoms using the Rutherford-Becker classifica-
ion and a walking impairment questionnaire. The ABI was
easured in both lower extremities. All assessments were
erformed pre-procedure, before hospital discharge, and at
and 12 months post-procedure.
ntervention. The SFA interventions were performed using
F or 7F arterial sheaths inserted through the contralateral
ommon femoral artery. Diagnostic imaging of the femoro-
opliteal arteries was performed using digital subtraction an-
iography. Crossing of the SFA lesions, lesion preparation,
nd stent implantation was performed using standard percu-
aneous interventional techniques. If patients required stent
mplantation, they were randomly assigned to 1 of the 2
reatment strategies. After successful stent implantation, post-
ilation was performed with either a cryoplasty or a conven-
ional balloon per the randomized treatment assignment.
onventional balloon dilation of the stent to ensure its maxi-
al expansion could be performed before cryotherapy. Cryo-
lasty was delivered using the PolarCath peripheral dilation
ystem, which consists of a balloon catheter, nitrous oxide
anister, and a microprocessor-controlled inflation unit. The
nflation unit activates the device through a pre-programmed
eries of steps, resulting in the inflation of the cryoplasty
alloon at 8 atm for 20 s to deliver nitrous oxide, which brings
he outer balloon temperature to 10°C, followed by a
eflation and rewarming phase. Final post-intervention angio-
rams were recorded with digital subtraction angiography
sing projections similar to diagnostic angiography.
Technical success was defined as 10% diameter stenosis
ithin the stented segment after balloon post-dilation. The
tudy protocol allowed inclusion of patients with bilateral
Abbreviations
and Acronyms
ABI  ankle-brachial index
SFA  superficial femoral
arteryymptomatic SFA disease. The post-dilation strategy was
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Cryoplasty Post-Dilation of Peripheral Stents October 9, 2012:1352–9randomly assigned for the first limb, and the contralateral
SFA segment was treated with the opposite post-dilation
strategy. Such staged procedures were separated by at least
30 days. After each procedure, patients were admitted to the
hospital and monitored for periprocedural complications for
at least 24 h, and discharged on indefinite aspirin therapy
(81 mg/day) and at least 30 days of clopidogrel (300 mg
loading dose followed by 75 mg/day).
Duplex ultrasonography assessment. All duplex ultra-
sound studies were performed by experienced ultrasonography
technicians with 5 to 12 MHz linear-array transducers and
were analyzed off-line in a blinded fashion. The extremity was
positioned in a neutral position, and the SFA segment was
identified. The ultrasound probe was positioned perpendicular
to the surface for optimal gray scale imaging of the arterial wall
and stented segment. Duplex imaging was performed using an
angle of 60° between the Doppler insonation beam and vessel
wall. Color Doppler interrogation (with pulse repetition fre-
quency scale adjusted to show normal laminar flow as a region
of homogeneous flow) was performed to detect a high-velocity
jet, suggestive of significant stenosis. Maximum peak systolic
velocity was measured at 4 different locations: proximal to the
stent (reference segment), within 10 mm of the proximal stent
edge, within the stent, and within 10 mm distal of the stent.
The ratio of the maximum peak systolic velocity recorded
within the stent and within 10 mm of the proximal and distal
edge to the maximum reference segment was calculated.
Patients who met the primary endpoint were allowed to
undergo angiographic evaluation and revascularization at the
discretion of the treating physician. If the SFA was occluded
proximal to the stent or if a single or multiple lesions were
treated in the stented SFA segment, then angiographic reste-
nosis was considered to have occurred.
Statistical analysis. We calculated a priori that 43 vascular
segments would be needed in each study arm to have 80%
power to detect a reduction in binary restenosis from 65% in
the conventional balloon post-dilation to 35% in the cryoplasty
post-dilation arm, assuming 10% attrition and an alpha of
0.05. Continuous variables were summarized as mean  SD
nd compared using t test or the Wilcoxon rank-sum test, as
ppropriate. Discrete variables were presented as frequencies,
nd group percentages compared using the chi-square test or
isher’s exact test, as appropriate. Freedom from restenosis was
ssessed using Kaplan-Meier curves and the log-rank test. For
ll comparisons a 2-sided probability of 0.05 was considered
tatistically significant. All analyses were performed using SAS
ersion 9.1 (SAS Institute, Cary, North Carolina).
esults
atients. In all, 121 consecutive patients consented, and 74
atients with 90 stented SFA segments were enrolled
Fig. 1). Forty-seven patients (39%) were not included
ecause stent implantation was not performed, or they did
ot meet the eligibility criteria or withdrew consent. The
rimary indication for stent implantation was 50% resid- bal stenosis after balloon pre-dilation. Baseline demo-
raphic, disease management, and procedural characteristics
or treated patients and lesions are shown in Tables 1 and 2.
n the cryoplasty group, 87%, 6%, and 7% of patients
resented with Rutherford-Becker stages 3, 4, and 5 symp-
oms, respectively. In the conventional balloon dilation
roup, 86%, 12%, and 2% presented with Rutherford-
ecker stages 3, 4 and 5 symptoms, respectively. The
.M.A.R.T. CONTROL (Cordis, Bridgewater, New Jer-
ey) nitinol self-expanding stent was used in 87% of lesions;
% received LifeStent (Bard, Tempe, Arizona), 3% Sentinol
Boston Scientific), 1% each Everflex (ev3, Plymouth, Min-
esota) and Absolute (Abbott, Santa Clara, California), and
% of lesions received 1 stent type.
tent post-dilation. Lesion length and implanted stent
imensions were similar in both treatment groups (Tables 1
nd 2). Nitinol self-expanding stents were implanted in all
ases. Patients with bilateral interventions had significantly
ore total occlusions (p  0.04), required post-dilation
alloons with larger diameters (p  0.05), and greater
umber of post-dilations (p  0.02) (Table 1). One-half of
he lesions were total occlusions, with longer lesion and
tent lengths compared to lesions without total occlusions
see Online Tables 1A and 1B). Analysis of lesion-based
reatment assignments revealed use of larger post-dilation
alloon diameters in the conventional balloon angioplasty group,
Figure 1 Study Flow Chart
Excluded from stent-based primary analysis: in the cryoplasty group, 4 arterial
segments excluded from analysis (2 died in cryoplasty group and 1 in bilateral
treatment group); and in the conventional balloon post-dilation arms, 2 arterial
segments excluded from analysis (1 died in conventional group and 1 in bilat-
eral group). B/L  bilateral; DM  diabetes mellitus; DUS  duplex ultra-
sound; nSES  nitinol self-expanding stents; SFA  superficial femoral artery.ut balloon lengths and number of inflations were similar in both
n recep
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October 9, 2012:1352–9 Cryoplasty Post-Dilation of Peripheral Stentstreatment groups (Table 1), as were procedural complications
(Table 3). Conventional balloon dilation of stents before
cryoplasty was performed in 51% of patients enrolled in the
cryoplasty arm. Minimal luminal diameter of lesions in the
cryoplasty and conventional balloon post-dilation arms were
0.86 0.95 mm and 0.89 1.12 mm, respectively (p 0.80).
Post-stent dimensions were 5.50 0.98 mm in the cryoplasty
arm and 5.54 1.00 mm in the conventional arm (p 0.91).
Acute gain was 4.56  1.41 mm in the cryoplasty arm and
4.67  1.42 mm in the conventional arm (p  0.73).
The ABI immediately after the intervention was 0.96 
0.14 in the cryoplasty group and 0.89  0.21 in the
conventional balloon dilation group (p 0.001 compared to
Patient Treatment AssignmentTable 1 Patient Treat ent Assignment
Variables
Cryoplasty Group
(n  29)
C
Demographics and risk factors
Age, yrs 62.9 15.1
Male 22 (76)
Hypertension 28 (97)
Diabetes mellitus 29 (100)
Hyperlipidemia 27 (93)
Tobacco use 15 (52)
Chronic kidney disease 2 (7)
Coronary artery disease 18 (62)
Disease management
Glycosylated hemoglobin 7.38 1.51
Insulin-requiring diabetes 4 (14)
Aspirin 21 (72)
Clopidogrel 13 (45)
Warfarin 5 (17)
Lipid-lowering therapy 25 (86)
Beta-blocking agents 18 (62)
ACEI/ARB 25 (86)
Hemoglobin, g/dl 13.37 1.66
Platelet count, k/mm3 227.14 75.09
Serum creatinine, mg/dl 1.17 0.38
Lesions and procedural features
Rutherford stage 3.18 0.55
Baseline ABI 0.60 0.20
Lesion length, mm 93.30 (73.80–251.50)
Number of run-off vessels 2.29 0.91
Chronic total occlusions 14 (48)
Stent length, mm 120 (80–270)
Stent diameter, mm 6.17 0.59
Use of debulking strategy 10 (34)
Post-dilation balloon length, mm 82.29 25.1
Post-dilation balloon diameter, mm 5.27 0.56
Number of dilations 2.38 1.79
Fluoroscopy time, min 31.41 20.11
Procedure duration, min 104 43
Mean activated clotting time 244.28 32.57
Values are mean  SD, n (%), or median (interquartile range). Baseline demographic, disease m
conventional or bilateral limb treatments. *The p value compares cryoplasty and conventional gr
bilateral groups.
ABI  ankle-brachial index; ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensibaseline for both groups).Follow-up. During the 12-month follow-up period, 5
patients died: 3 patients in the cryoplasty arm, 1 patient in
the conventional balloon post-dilation arm, and 1 patient
who underwent bilateral intervention. None of the deaths
was related to the index procedure, and deaths were not
significantly different between the 2 study arms (p  0.31).
Three deaths were sudden cardiac death, and 2 were
secondary to infection and sepsis. Thus, duplex ultrasonog-
raphy and clinical follow-up at 12 months were available in
41 (91.1%) arterial segments in the cryoplasty arm and 43
(95.5%) segments in the conventional balloon post-dilation
arm, respectively (Fig. 1). Medical management of patients
post-intervention was similar in both treatment groups.
tional Balloon
up (n  29)
Bilateral Group
(n  16) p Value
93 10.25 63.1 8.4 0.94*, 0.99†, 0.99‡
27 (93) 15 (94) 0.15*, 0.71†, 0.59‡
28 (97) 16 (100) 0.47*, 1.00†, 1.00‡
29 (100) 16 (100) 1.00*, 1.00†, 1.00‡
26 (90) 16 (100) 0.94*, 0.99†, 0.99‡
16 (55) 10 (63) 1.00*, 0.59†, 0.76‡
4 (14) 2 (13) 0.67*, 0.61†, 1.00‡
17 (59) 12 (75) 1.00*, 0.51†, 0.34‡
65 2.16 7.55 2.17 0.53*, 0.87†, 0.34‡
7 (24) 3 (19) 0.50*, 0.69†, 1.00‡
17 (59) 10 (63) 0.41*, 0.52†, 1.00‡
13 (45) 5 (31) 1.00*, 0.53†, 0.53‡
1 (3) 1 (6) 0.19*, 0.40†, 1.00‡
19 (66) 15 (94) 0.12*, 0.64†, 0.07‡
21 (72) 10 (63) 0.58*, 1.00†, 0.52‡
19 (66) 11 (69) 0.52*, 1.00†, 1.00‡
.62 2.08 14.13 1.72 0.94*, 0.52†, 0.41‡
.72 73.35 246.22 105.22 0.56*, 0.48†, 0.78‡
11 0.33 1.1 0.2 0.52*, 0.50†, 0.91‡
18 0.48 3.13 0.42 1.00*, 0.75†, 0.73‡
59 0.20 0.63 0.20 0.85*, 0.63†, 0.52‡
(70–202.40) 116.30 (90–216.20) 0.67*, 0.60†, 0.64‡
88 0.96 2.08 0.83 0.10*, 0.45†, 0.49‡
10 (34) 11 (69) 0.42*, 0.22†, 0.04‡
0 (90–220) 195 (104.75–307.50) 0.43*, 0.25†, 0.22‡
17 0.37 5.97 0.31 1.00*, 0.22†, 0.07‡
8 (28) 6 (38) 0.78*, 1.00†, 0.52‡
68 43.46 89.09 41.26 0.88*, 0.49†, 0.69‡
62 0.79 5.19 0.40 0.06*, 0.62†, 0.05‡
93 0.98 2.72 1.13 0.24*, 0.50†, 0.02‡
76 20.08 34.13 20.95 0.62*, 0.67†, 0.40‡
04 33 121 43 0.97*, 0.20†, 0.23‡
.09 32.37 233.59 32.60 0.63*, 0.30†, 0.52‡
ent and procedural characteristics, based on patient assignments to unilateral limb cryoplasty,
The p value compares cryoplasty and bilateral groups. ‡The p value compares conventional and
tor blocker; IQR  interquartile range.onven
Gro
65.
7.
13
238
1.
3.
0.
120
1.
16
6.
83.
5.
1.
28.
1
240
anagem
oups. †Glycosylated hemoglobin level for the cryoplasty arm was
b
L
7
(
a
R
2
0
9
(
r
b
g
0
s
c
a
i
i
0
g
E
i
b
s
1356 Banerjee et al. JACC Vol. 60, No. 15, 2012
Cryoplasty Post-Dilation of Peripheral Stents October 9, 2012:1352–97.43  1.77 at baseline and 7.46  1.57 at 12 months (p 
0.96). For the conventional arm, it was 7.63  2.16 at
aseline and 7.11  1.36 at 12 months (p  0.24).
ow-density lipoprotein levels for the cryoplasty arm were
2.83  28.73 at baseline and 64.73  24.17 at 12 months
p  0.25). In the conventional arm, it was 87.10  34.51
t baseline and 75.18  35.19 at 12 months (p  0.25).
ate-pressure product for the cryoplasty arm was 9,894 
,360 at baseline and 9,310  2,315 at 12 months (p 
.64). Rate-pressure product for the conventional arm was
,608  2,036 at baseline and 9,093  2,072 at 12 months
p  0.17). At 12 months, 16% of patients in both groups
eported active tobacco use.
Binary restenosis occurred in 55.8% in the conventional
Superficial Femoral Artery Lesions Treatment AsTable 2 Superficial Femoral Artery Lesions T
Variables
Cryoplasty
(n  4
Demographics and risk factors
Age, yrs 62.9
Male 37 (82
Hypertension 44 (97
Diabetes mellitus 45 (10
Hyperlipidemia 43 (95
Tobacco use 25 (55
Chronic kidney disease 4 (8.9
Coronary artery disease 30 (66
Disease management
Glycosylated hemoglobin 7.43
Insulin-requiring diabetes 7 (15.
Aspirin 31 (68
Clopidogrel 18 (4
Warfarin 6 (13.
Lipid lowering therapy 40 (88
Beta-blocking agents 28 (62
ACEI/ARB 36 (8
Hemoglobin, g/dl 13.6
Platelet count, k/mm3 236.1
Serum creatinine, mg/dl 1.14
Lesions and procedural features
Rutherford stage 3.18
Baseline ABI 0.59
Lesion length, mm 100 (78.38
Number of run-off vessels 2.1
Chronic total occlusions 25 (55
Stent length, mm 150 (80–
Stent diameter, mm 6.09
Use of debulking strategy 16 (35
Post-dilation balloon length, mm 83.53
Post-dilation balloon diameter, mm 5.23
Number of dilations 2.51
Fluroscopy time, min 32.14
Procedure duration, min 111
Mean activated clotting time 241.99
Values are mean  SD, n (%), or median (interquartile range). Baselin
on superficial femoral artery assignment to either cryoplasty or conven
on those recorded in patients’ charts at enrollment.
Abbreviations as in Table 1.alloon dilation group, compared to 29.3% in the cryoplasty croup (p  0.01, odds ratio: 0.36, 95% confidence interval:
.15 to 0.89) (Fig. 2A). Cumulative hazard of restenosis is
hown in Figure 2B (p  0.02, hazard ratio: 2.28, 95%
onfidence interval: 1.14 to 4.61). Cumulative hazard of
ll-cause death and restenosis is 2.39 (95% confidence
nterval: 1.19 to 4.78, p  0.01).
Compared to baseline, the ABI at 12 months was higher
n the cryoplasty group (0.59  0.21 to 0.77  0.30, p 
.004) but was unchanged in the conventional post-dilation
roup (0.62  0.19 to 0.65  0.26, p  0.66) (Fig. 3).
xcluding patients with bilateral treatment, the mean walk-
ng impairment scores at 12 months were similar (p 0.53),
ut were higher compared to baseline in both treatment
trategy groups (cryoplasty, 1,406 to 6,157, p  0.005;
mentent Assignment
Conventional Balloon Group
(n  45) p Value
64.9 9.6 0.42
42 (93.3) 0.11
43 (95.5) 0.56
45 (100) 1.00
42 (93.3) 0.65
27 (60) 0.76
6 (13.3) 0.59
29 (64.5) 0.70
7.63 2.16 0.67
10 (22.2) 0.39
27 (60) 0.38
24 (53.3) 0.21
2 (4.4) 0.14
34 (75.6) 0.10
32 (71.1) 0.38
31 (68.9) 0.23
13.8 1.9 0.73
238.2 81.9 0.91
1.11 0.29 0.60
3.14 0.41 0.66
0.62 0.19 0.50
) 120 (78.40–223) 0.45
2.0 0.9 0.60
20 (44.3) 0.06
180 (100–290) 0.29
6.10 0.30 0.87
12 (26.7) 0.45
86.18 44.16 0.72
5.51 0.72 0.02
2.17 1.01 0.25
31.52 20.63 0.90
112 47 0.86
234.54 31.95 0.37
graphic, disease management, and procedural characteristics based
ost-dilation strategies. All diagnoses and laboratory values are basedsignreat
Group
5)
13.0
.2)
.8)
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.5)
.6)
)
.7)
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6)
.9)
0)
3)
.9)
.2)
0)
1.7
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0.33
0.54
0.21
–245
0.9
.6)
270)
0.55
.6)
28.69
0.51
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20.25
34
31.95
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October 9, 2012:1352–9 Cryoplasty Post-Dilation of Peripheral Stents0.002). For the cryoplasty group, Rutherford stage was
3.18  0.54 at baseline, 0.94  1.16 at 6 months (p 
0.0001), and 1.51 1.56 at 12 months (p 0.0001). In the
onventional treatment arm, Rutherford stage was 3.14 
.41 at baseline, 1.33 1.33 at 6 months (p 0.0001), and
.50 1.42 at 12 months (p 0.0001). There was no significant
ifference in Rutherford stages between the 2 study arms at
aseline or at 6 months and 12 months of follow-up.
Among SFA segments with a total occlusion at baseline
n  45), 70% in the conventional post-dilation group and
36% in the cryoplasty group had binary restenosis (p  0.06).
or bilaterally treated SFA segments (n  16), 66.7% in the
onventional post-dilation group and 26.7% in cryoplasty
roup had in-stent restenosis (p  0.03). These treatments
ere separated by a mean interval of 3.9  0.4 weeks.
Adverse EventsTable 3 Adverse Events
Complication n/Events
Death 5
Amputation or surgical revascularization 0
Myocardial infarction, stroke or acute renal failure 0
Pseudoaneurysm* 4
Hematoma* 3
Arterial dissections* 2
Arteriovenous fistula* 1
Closure device failure* 1
Retroperitoneal hematoma* 0
Distal embolization* 0
Residual thrombus* 1
Allergic reaction to contrast* 1
*Procedure-related adverse events and complications.
Figure 2 Endpoints
(A) 12-month binary restenosis, the primary study endpoint comparing nitinol self-
catheters in patients with diabetes mellitus. (B) Cumulative hazard of restenosis
tion strategies of nitinol self-expanding stents implanted in the superficial femoralAngiographic follow-up was obtained for all patients who
met the primary endpoint in the cryoplasty group and for
75% of patients in the conventional balloon dilation group
(p  0.19). Target vessel revascularization procedures were
performed in 17.8% and 26.7% of SFA segments in the
cryoplasty group and conventional balloon dilation group,
respectively, and the remaining were medically managed.
Target lesion revascularization in the cryoplasty arm was 10%
compared to 16% in the conventional arm (p  0.29).
Restenosis patterns were similar in both treatment groups. In
the cryoplasty group, 33% were occlusions and the rest were
diffuse restenosis; in the conventional arm, 29% were occlu-
sions and the rest were diffuse restenosis (p  0.74, for
occlusions). One stent fracture (2.5%) was reported in the
cryoplasty group; none was found in the conventional balloon
Description
ne periprocedurally; cryoplasty 3, conventional 1, bilateral treatment group 1;
3 died of sudden cardiac death and 2 died secondary to infection/sepsis
o in cryoplasty, 2 in conventional treatment group
ludes 2 (5 cm in diameter) and 1 (large 5 cm) at groin access site, managed
conservatively; all 3 in cryoplasty group
e in cryoplasty and 1 in conventional treatment groups
e in conventional treatment group
d to pseudoaneurysm and groin access site hematoma, managed conservatively;
1 in cryoplasty group
n–flow-limiting residual angiographic opacity in distal superficial femoral artery at
end of procedure; 1 in conventional group
in cryoplasty group
ing post-dilation strategies with either cryoplasty or conventional balloon dilation
2 months for cryoplasty (blue line) and conventional balloon (red line) post-dila-
of patients with diabetes mellitus.No
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and 6.7% in the cryoplasty group and conventional balloon
dilation group, respectively (p  0.50), and were predomi-
antly related to access site (Table 3). No patients were referred
or procedure-related surgical revascularization or amputation.
iscussion
he key finding of this study is that, for patients with
iabetes mellitus who underwent SFA stenting using self-
xpanding stents, post-dilation using cryoplasty significantly
educed the 12-month in-stent restenosis rates compared to
ost-dilation using a conventional balloon.
Implantations of stents in the SFA have significantly
mproved periprocedural and long-term outcomes; how-
ver, the durability of stents is limited by restenosis
9,10). The FAST (Femoral Artery Stenting Trial) re-
orted no difference in 1-year binary restenosis rates with
alloon angioplasty and nitinol stent implants in the SFA
11). In contrast, data from 3 other randomized trials—the
BSOLUTE (Randomized Comparison between Siroli-
us [Cypher]/Sirolimus-Analogous [Xience; Promus] vs.
aclitaxel [Taxus vs. Costar] Eluting Stents in Coronary
esions) trial (12,13), the RESILIENT (Randomized
tudy Comparing the Edwards Self-Expanding LifeStent
ersus Angioplasty-Alone in Lesions Involving the Super-
cial Femoral Artery and/or Proximal Popliteal Artery) trial
14], and the Zilver PTX trial (15)—showed improved
rimary stent patency at 12 months (12,14,15) and at 24
onths (13) compared to angioplasty, especially with
aclitaxel-eluting stents (15). The mean lesion lengths of
emoropopliteal arterial segments included in the FAST,
ESILIENT, ABSOLUTE, and Zilver PTX trials were 45
m, 67 mm, 97 mm, and 65 mm, respectively.
Despite this evidence, there are limited data, and to the
est of our knowledge no published randomized trials of
ndovascular treatment of peripheral arterial disease in
Figure 3 Change in ABI
Ankle-brachial index (ABI) for post-dilation conventional group (red bars) and
cryoplasty group (blue bars) at baseline (pre-intervention), hospital discharge,
and 12 months post-procedure.iabetic patients with long segment SFA stenting. Diabetic ipatients have more diffuse and angiographically more severe
peripheral arterial disease than nondiabetic patients (16).
Femoropopliteal stenting remains highly prevalent among
patients with diabetes mellitus, given the poor patency rates
after balloon angioplasty of long or occluded SFA segments
(2,17,18). Thus, a strategy to improve stent outcomes in diabetic
patients using cryoplasty was tested in the COBRA trial.
Although the mechanism of cryoplasty continues to be
debated and actively researched, it is widely accepted that
cryoplasty, by delivering cryotherapy precisely at10°C to the
arterial wall (19), induces smooth muscle cell apoptosis while
limiting cell necrosis (7). In the present investigation, it was
hypothesized that cryoplasty may reduce restenosis, especially
in diabetic patients, who already have a greater smooth muscle
cell proliferative response to vascular injury (20).
Prior studies involving cryoplasty have reported either im-
proved patency rates (21,22) or higher restenosis rates
(21,23,24), including 1 demonstrating lower patency in a
diabetic population compared to balloon angioplasty (25).
However, all such studies were retrospective and observational.
In a single-center randomized trial, Jahnke et al. (26)
reported a 9-month patency rate of 79% with cryoplasty
compared to 67% with conventional balloon angioplasty (p 
.14) for focal popliteal artery occlusive disease. Laird et al.
27), in a prospective, multicenter trial of cryoplasty for
emoropopliteal disease reported a clinical patency of 82.2%
nd primary patency determined by duplex ultrasonography of
0.1% at 9 months. Both of these studies evaluated focal
esions and lesions that were not high risk, and they did not use
ryotherapy adjunctive to stents. The COBRA study is the first
rial to deliver cryotherapy in addition to a vascular scaffold,
hich are often used to treat complex SFA disease (28,29) as
strategy to limit smooth muscle cell proliferation and reduce
n-stent restenosis.
An important study by Karthik et al. (30) evaluated cryo-
lasty for the treatment of in-stent restenosis in femoropopli-
eal distribution and reported no efficacy. These findings are in
ontrast to those observed in the COBRA trial. This difference
n outcomes can be potentially attributed to the biological
eterogeneity of nascent vascular smooth muscle cells of the
rterial wall, compared to its proliferation in restenotic lesions
31). Vascular smooth muscle cells of an atherosclerotic arterial
all are known to be associated with greater proliferative
ctivity, enhanced migratory capacity, poor level of differenti-
tion, and much higher sensitivity to apoptotic stimuli com-
ared to a restenotic response (31).
The complexity of SFA lesions treated in the COBRA
rial is greater than those in prior randomized studies
erformed in this area. A comparison of outcomes in the
otal occlusion and bilateral treatment groups provides the
pportunity to analyze the effect of cryoplasty for stent
ost-dilation in complex and unbiased subsets unique to this
rial. The strategy of affecting outcomes with a post-dilation
alloon may also be relevant to drug-coated stents.
Our study is limited by the relatively small number of patientsncluded, although it is the first peripheral intervention trial to
1359JACC Vol. 60, No. 15, 2012 Banerjee et al.
October 9, 2012:1352–9 Cryoplasty Post-Dilation of Peripheral Stentsexclusively enroll diabetic patients. The results could also have
been affected by the type of nitinol stent implanted, although most
stents were of a single type, and by the lack of a systematic
radiographic monitoring for stent fracture. Finally, the pre-stent
implantation strategies, along with other periprocedural aspects,
were also at the discretion of the primary operator, but it reflects
the contemporary clinical practice in this area. The findings of this
proof-of-concept trial need to be studied in a larger, randomized
controlled trial with a greater diversity of patients.
Conclusions
Post-dilation of SFA stents with cryoplasty can significantly
reduce the risk of restenosis in patients with diabetes mellitus.
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